Memphasys Limited has revised its FY25 financials to reflect a $1.12 million liability linked to uncertain compliance with R&D tax incentive rules, pending a private tax ruling.
Memphasys Limited is intensifying its commercial push for Felix, an innovative automated sperm separation system for IVF, backed by a landmark Middle East partnership and a fresh capital raise to scale manufacturing and sales.
